Regenicin, Inc. Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2022-06-30..
Operating margin
Overview →Financial period ending 2022-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2022-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -558.52K USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2022-06-30 | $-558.52K | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-561.36K | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-631.58K | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $-635.86K | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-525.67K | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-532.16K | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-469.28K | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $-510.82K | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $-662.43K | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $-676.61K | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-689.91K | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $-736.55K | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $-523.98K | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-576.23K | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $-540.28K | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $-803.92K | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $-816.95K | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-883.84K | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $-961.11K | (m) | (m) | $5.28K | (m) | (m) |
| 2017-06-30 | $-596.03K | (m) | (m) | $5.28K | (m) | (m) |
| 2017-03-31 | $-706.53K | (m) | (m) | $5.28K | (m) | (m) |
| 2016-12-31 | $-700.40K | (m) | (m) | $5.99K | (m) | (m) |
| 2016-09-30 | $-779.85K | (m) | (m) | $1.45K | (m) | (m) |
| 2016-06-30 | $-285.14K | (m) | (m) | $6.45K | (m) | (m) |
| 2016-03-31 | $-1.39M | (m) | (m) | $6.45K | (m) | (m) |
| 2015-12-31 | $-1.43M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $-241.82K | (m) | (m) | $38.40K | (m) | (m) |
| 2015-06-30 | $-1.06M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $-712.60K | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $306.46K | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $-725.89K | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $-3.92M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | $-679.14K | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.